Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call March 26, 2026 8:00 AM EDT
Company Participants
Yuly Chen
Dajun Yang – Co-Founder, Chairman & CEO
Veet Misra – Chief Financial Officer
Zhichao Si – Head of Commercial
Conference Call Participants
Lut Ming Cheng – JPMorgan Chase & Co, Research Division
Biren Amin – Piper Sandler & Co., Research Division
Supawat Thongthip – Truist Securities, Inc., Research Division
Jeet Mukherjee – BTIG, LLC, Research Division
Matthew Biegler – Oppenheimer & Co. Inc., Research Division
Christopher Liu – Lucid Capital Markets, LLC, Research Division
Michael King – Rodman & Renshaw Research
Presentation
Operator
Good day, everyone, and welcome to Ascentage Pharma’s 2025 Annual Results Earnings Call. [Operator Instructions] As a reminder, today’s call is being recorded.
Thank you for joining us. I will now turn the call over to Yuly Chen, Senior Director of Investor Relations for the safe harbor statement. Yuly, please go ahead.
Yuly Chen
Thank you, operator. Please note that today’s discussion will include forward-looking statements based on our current expectations and assumptions. These statements involve risks and uncertainties and actual results may differ materially. For a full discussion of these risks, please refer to our filings and disclosures.
On today’s call, I am joined by Dr. Dajun Yang, Chairman and CEO, who will provide an overview of recent developments and 2025 annual performance. As well as Dr. Veet Misra, CFO, who will go through the financial highlights. The presentation will then be followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Yifan Zhai, Chief Medical Officer; Dr. Shaomeng Wang, Cofounder, Chief Scientific Adviser, Dr. Zhichao Si, Head of Commercial, I will now turn the call over to Dr. Yang.
Dajun Yang
Co-Founder, Chairman & CEO
Thank you. Good morning. I’m Dajun Yang, Chairman and CEO of the company. Today, I’m very
Credit: Source link
